Amgen issues statement regarding MariTide Phase 1 data
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies
Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...
Le Lézard3h
73% of enterprises have launched AI, including generative AI, across marketing with 52% of deployments achieving business value: Infosys CMO Radar
Infosys Knowledge Institute, a research arm of Infosys (NSE: INFY) (BSE: INFY) , a global leader in next-generation digital services and consulting, today unveiled a global research report titled ...
Le Lézard4h
Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance
Fourth Frontier, a medical technology company based out of New York and Bangalore, announced the 510(k) clearance of the ...
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...